520 related articles for article (PubMed ID: 29190379)
1. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus.
Wiederhold NP; Patterson HP; Tran BH; Yates CM; Schotzinger RJ; Garvey EP
J Antimicrob Chemother; 2018 Feb; 73(2):404-408. PubMed ID: 29190379
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
González GM
Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
[TBL] [Abstract][Full Text] [Related]
4.
Nishimoto AT; Wiederhold NP; Flowers SA; Zhang Q; Kelly SL; Morschhäuser J; Yates CM; Hoekstra WJ; Schotzinger RJ; Garvey EP; Rogers PD
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910896
[TBL] [Abstract][Full Text] [Related]
5. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
7. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
8. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
[TBL] [Abstract][Full Text] [Related]
9. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
10. Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong
Schell WA; Jones AM; Garvey EP; Hoekstra WJ; Schotzinger RJ; Alexander BD
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956419
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.
Espinel-Ingroff A
J Clin Microbiol; 1998 Jan; 36(1):198-202. PubMed ID: 9431946
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
13. The Fungal Cyp51-Specific Inhibitor VT-1598 Demonstrates
Wiederhold NP; Lockhart SR; Najvar LK; Berkow EL; Jaramillo R; Olivo M; Garvey EP; Yates CM; Schotzinger RJ; Catano G; Patterson TF
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30530603
[No Abstract] [Full Text] [Related]
14. The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.
Lockhart SR; Fothergill AW; Iqbal N; Bolden CB; Grossman NT; Garvey EP; Brand SR; Hoekstra WJ; Schotzinger RJ; Ottinger E; Patterson TF; Wiederhold NP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2528-31. PubMed ID: 26787697
[TBL] [Abstract][Full Text] [Related]
15. The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.
Wiederhold NP; Shubitz LF; Najvar LK; Jaramillo R; Olivo M; Catano G; Trinh HT; Yates CM; Schotzinger RJ; Garvey EP; Patterson TF
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437615
[TBL] [Abstract][Full Text] [Related]
16. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
17. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
Marangon FB; Miller D; Giaconi JA; Alfonso EC
Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
[TBL] [Abstract][Full Text] [Related]
18. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
Espinel-Ingroff A
J Clin Microbiol; 1998 Oct; 36(10):2950-6. PubMed ID: 9738049
[TBL] [Abstract][Full Text] [Related]
19. Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity.
Hargrove TY; Garvey EP; Hoekstra WJ; Yates CM; Wawrzak Z; Rachakonda G; Villalta F; Lepesheva GI
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461309
[TBL] [Abstract][Full Text] [Related]
20. In vitro polymyxin activity against clinical multidrug-resistant fungi.
Yousfi H; Ranque S; Rolain JM; Bittar F
Antimicrob Resist Infect Control; 2019; 8():66. PubMed ID: 31044071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
